- PharMerica (PMC +25.7%) soars after smashing the estimate of analysts with its Q3 report.
- Results were boosted by cost-containment measures and an industry-leading generic dispensing rate of 83.3%.
- The company boosted its forecast for full-year EPS to $1.71-$1.76, up from a prior range of $1.55-$1.60 and above the consensus estimate of analysts of $1.60.(PR)
at Zacks.com (Fri, 8:43AM)